Group CEI (n = 40) | Group PIEB (n = 44) | p-value | HL-Estimator (95% CI) | |
---|---|---|---|---|
LA PCA Bolus d0-d2, ml | 28 (12–64) | 10 (2–28) | 0.002* | 16 (4; 28) |
LA PIEB/CEI amount d0-d2, ml | 323.5(286.6–336.7) | 311.4 (263–330.2) | 0.161 | 10.2 (−4; 30.6) |
Overall LA consumption d0-d2, ml | 350.3 (326.5–380.8) | 329 (291–341.1) | 0.003 | 29.55 (10.7;52.1) |
LA PCA Bolus d0, ml | 0 (0–8) | 0 (0–4) | 0.046 | 0 (0; 0) |
LA PCA Bolus d1, ml | 18 (4–26) | 4 (0–14) | 0.002* | 8 (4; 16) |
LA PCA Bolus d2, ml | 12 (4–34) | 4 (0–12) | 0.010* | 4 (0; 12) |
LA PIEB/CEI amount d0, ml | 50.9 (36–55.7) | 48 (36–54) | 0.238 | 2.9 (−1,8; 6.8) |
LA PIEB/CEI amount d1, ml | 140.9 (132.4–145.2) | 132.3 (120–141.7) | 0.015* | 8.3 (1.2; 17.2) |
LA PIEB/CEI amount d2, ml | 135.2 (110.6–141.4) | 131 (109.5–140.1) | 0.588 | 2.3 (−6.6; 11) |